TickerTalks
Browse all tickers →
TickerTalks›$AZTA
AZAZTA

Azenta, Inc.

$AZTA·$1.5B·Medical - Instruments & Supplies·Healthcare
$33.38-1.6%YTD-9.9%1Y+9.1%
Mentions · last 7 days
2026-08-08: 0 posts2026-08-09: 1 posts2026-08-10: 1 posts2026-08-11: 1 posts2026-08-12: 1 posts2026-08-13: 0 posts2026-08-14: 12 posts16+20%
Price updated 17h ago·X counts updated 16h ago
AZAZTA
$AZTAAzenta, Inc.
$33.38-1.56%16 posts+20%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $AZTA, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Proven numbersAcceleratingAI verdict · as of 2026-08-15

The move is getting stronger, with heavier trading behind it.

Azenta at 68% of 52-week range on Q3 double beat plus PT upgrades — the life-sciences-sample-management franchise is gap-filling.

Azenta, Inc. is a global provider of life-sciences sample management and preservation solutions — the specific franchise supplying biobanking equipment, cryogenic storage, sample processing, and multiomics services to pharma R&D and clinical-trial customers. It's up 9% over twelve months as the sample-management category has stabilized post-2024 biotech-funding pullback.

Where it stands:

  • Q3 was a decisive beat with PT upgrades — EPS of $0.16 beat the $0.11 estimate by 41% (Q2 EPS missed by 140% on a small base), Q1 revenue grew 1% year-over-year to $145M, and the beat plus specific 'double beat' framing plus PT upgrades combine into the setup that has driven today's post-print momentum.
  • The gap-fill technical setup is the tape catalyst — the sample notes traders booking 16-33% returns on the August $35 calls at $0.60-$0.80 following the double beat, PT upgrades, and gap-fill play setup, so the options-momentum crowd has been active and the underlying tape has followed the fundamental positive.
  • The insider signal is small and mixed — officer Ephraim Starr bought $8K on Aug 4 (small P-Purchase), plus Aug 11 CAO appointment of Erik Bello (effective Aug 31), so the operational transition is happening at exactly the moment the operating results are improving — a positive alignment.

Q4 earnings Nov 17 is the read — a print with continued revenue-growth acceleration plus specific multiomics or sample-management segment commentary extends the trend and the negative-6x trailing PE looks better as forward EPS turns positive; a soft print or specific biotech-funding-cycle rollover and the 68%-of-52w-range position gets tested. Biotech-funding environment is the underappreciated multi-year swing factor either direction.

Agrees with X sentimentX captured the options-momentum trade correctly — 16-33% returns on the August $35 calls at $0.60-$0.80 following the double beat, PT upgrades, and gap-fill play setup. The uniformly constructive options-flow tone matches the tape; the fundamentals-plus-technicals combination is the actual bull setup.

What to watch: Q4 earnings Nov 17 — a print with continued revenue-growth acceleration plus multiomics or sample-management segment commentary extends the trend and the negative-6x trailing PE looks better as forward EPS turns positive; a soft print or biotech-funding-cycle rollover and the 68%-of-52w-range position gets tested. Biotech-funding environment is the multi-year swing factor.

On the calendar: 2026-11-17 — Q4 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment5 posts analyzed · as of 2026-08-12

Azenta traders are booking 16-33% returns on the August $35 calls at $0.60-$0.80 following a double beat, price-target upgrades and a gap-fill play setup. Options momentum is uniformly constructive and there are no bearish voices in the sample.

Read the AI verdict + X sentiment for $AZTA

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Provides biological sample storage, genomics sequencing services, and automated lab equipment to pharma and biotech researchers.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Instruments & Supplies sits in its cycle right now — and what that implies for $AZTA.

Medical - Instruments & Supplies · Healthcare

No material change from last week — Medline's prime vendor model wins market share as hospitals simplify sourcing, while bioprocessing component suppliers (WST, RGEN, AVTR) recover from the..

What this means for $AZTA

Neutral — Provides biological sample storage, genomics sequencing services, and automated lab equipment to pharma and biotech researchers; limited read-through from medical - instruments & supplies macro dynamics to this specific revenue mix.

Industry benchmark

10-name peer basket
+22.1%YTD
+21.3%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-5.9How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-0.7%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-2.6%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
2.7%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
1.8Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-10.7%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
44.6%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 4, 2026$0.16$0.11+40.6%
Q1 2026May 6, 2026$-0.04$0.10-140.0%
Q4 2025Feb 4, 2026$0.09$0.11-18.2%
Q3 2025Nov 21, 2025$0.21$0.19+10.8%
Next earningsTue, Nov 17·consensus EPS $0.16

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$144.8M+1.0%42.8%-10.6%$-3.49$4.8M
Q1 FY26$148.6M+0.8%42.9%-3.3%$-0.34$14.7M
Q4 FY25$159.2M+5.7%45.4%1.8%$1.03$-5.7M
Q3 FY25$143.9M-0.2%47.1%1.1%$-1.15$15.0M

Forward consensus

5-year forecast · up to 4 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$600.5M$590.4M – $603.7M$0.39$0.38 – $0.394
FY27$630.1M$619.6M – $633.5M$0.61$0.60 – $0.624
FY28$675.0M$663.7M – $678.7M$0.85$0.80 – $0.894
FY29$683.5M$672.0M – $687.2M$1.30$1.27 – $1.312
FY30$742.8M$730.3M – $746.8M$1.76$1.72 – $1.772

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.8×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.68%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+25.6%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+18.9%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 40.7M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.2% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.375-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

BuyJul 31Ephraim StarrSVP, Gen Counsel & Secretary335 sh$8KBuyMay 18William L CornogDirector10.0K sh$164K
+ 3 other (2 inkinds · 1 award) in window

See when $AZTA insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KOfficer or director changeAug 118-K — Item 5.02: Officer or director change
AI summary

Azenta (AZTA) appointed Erik J. Bello, age 51, as Vice President and Chief Accounting Officer, effective August 31, 2026, serving as principal accounting officer. Lawrence Lin continues as EVP and CFO. This is a routine accounting officer appointment.

8-KMaterial agreementJul 88-K — Item 1.01: Material agreement · Item 2.01: Acquisition completed · Item 7.01: Press release / Reg FD
AI summary

Azenta, Inc. (AZTA) completed the acquisition of B Medical Systems S.à r.l. from Thelema S.à r.l. on July 1, 2026. To facilitate closing, Azenta Germany GmbH provided Thelema a $35 million vendor loan at 6.0% per annum, secured by a pledge over 100% of B Medical Systems' equity, maturing 3 months after funding — a related-party transaction approved by the Audit Committee (Thelema is majority owned by VP/B Medical Systems CEO Luc Provost). The acquisition is complete with B Medical Systems now a wholly-owned subsidiary; the $35M vendor loan is a short-term bridge expected to be refinanced.

3New insider — initial holdingsApr 163
AI summary

Form filed by More than One Reporting Person Table I - Non-De filed a Form 3 (initial ownership statement) for AZTA on 2026-04-16, initiating required Section 16 reporting. Role: of Reporting Person. Form 3 is a mandatory administrative filing upon first becoming an insider or 10%+ holder; it does not reflect a purchase or sale event.

8-KOfficer or director changeApr 78-K — Item 5.02: Officer or director change · Item 7.01: Press release / Reg FD
AI summary

AZTA disclosed a personnel change (8-K Item 5.02, dated 2026-04-07). An executive departure and a new appointment are both reported. Personnel changes are generally administrative; materiality depends on seniority and circumstances.

8-KMaterial agreementMar 48-K — Item 1.01: Material agreement · Item 7.01: Press release / Reg FD
+ 9 other (2 10-Qs · 2 earnings 8-Ks · 2 13Gs · 1 SD) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Azenta: Needs To Overcome A Few Hurdles If The Rally Is To Continueseekingalpha.com·1d agoAzenta, Inc. $AZTA Shares Sold by Bank of New York Mellon Corpdefenseworld.net·9d agoArrowstreet Capital Limited Partnership Buys New Position in Azenta, Inc. $AZTAdefenseworld.net·9d agoAzenta, Inc. (AZTA) Q3 2026 Earnings Call Transcriptseekingalpha.com·10d agoAzenta Q3 Earnings Call Highlightsmarketbeat.com·10d ago

In themes

Explore the broader themes this ticker is being talked about under.

Robotics & HumanoidsAI Precision Medicine

More in Medical - Instruments & Supplies

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$BDX$ISRG$MDLN$AVTR$QDEL$LMAT$PLSE$WST
Voices on X · last 7 days

No standout posts about $AZTA on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport